drugset
drugset / Trial / NCT04752540

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment

NCT04752540 ↗

Phase 1 Completed 32 enrolled F2G Biotech GmbH
Non-randomizedParallel-groupOpen-labelOther

Summary

A single oral dose study to investigate the PK and safety of olorofim in mild and moderately hepatically impaired subjects compared to subjects with normal hepatic function.

Timeline

Start
2021-07-02
Primary completion
2021-10-24
Completion
2021-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Olorofim Small molecule 60 mg Oral
Subject Olorofim Small molecule 120 mg Oral

Indications

No indication recorded.